July 2020 Volume 16, Issue 7

Volume 16, Issue 7 | July 2020

July 2020

In this Issue

Research & Development

DDN Webinar: A CRISPR Focus on Editing

Recent advances push the gene-editing platform from analytic resource to therapeutic solution.

DDN Webinar: Synthetic DNA Technologies Enable Fast and Responsive Antibody-based Therapeutics and Diagnostics for SARS-CoV-2

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry.

DDN Webinar: Repurposing in a crisis: Tackling the COVID-19 wildfire

While the race for a vaccine targeting the SARS-CoV-2 coronavirus is expected to take another year or so, there is an increasingly urgent need to fight the disease in those already infected.
Drug Discovery News Placeholder Image

A closer look at splicing

Roswell Park study finds aggressive prostate cancer marked by abnormal RNA splicing

Discovery

A Network Approach to Target Validation

Walter Kolch, co-founder and director of Systems Biology Ireland discusses the merits of a network approach to target validation and why probing clinical samples early is critical to increasing drug development success.

OSE brings CLEC-1 to AACRR

CLEC-1 is a new therapeutic target for immuno-oncology. 
The research program focuses on developing a cancer immunotherapy targeting CLEC-1, a newly identified C-type lectin receptor, to block suppressive functions of myeloid cells and restore antitumor response to T lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T lymphocytes.
antibiotic-resistant bacteria

AI yields new antibiotic

 In their new study, the researchers also identified several other promising antibiotic candidates, which they plan to test further. They believe the model could also be used to design new drugs, based on what it has learned about chemical structures that enable drugs to kill bacteria.
 immunotherapy

IONTAS announces collaboration

Partnership with Inotrem will seek to identify novel immunotherapy targets
Drug Discovery News Placeholder Image

When in ROME...

ROME Therapeutics launches with a focus on repeatome-based drug discovery

Clinical Trials

Drug Discovery News Placeholder Image

Mastering MS

New drug could be 50 to 100 times more potent than existing options
Drug Discovery News Placeholder Image

Endogenous treatment for NASH

Axcella reports that AXA1125 performed well in models of NASH and diabetes
Drug Discovery News Placeholder Image

Accelerating clinical trials

Royal Philips initiative will run patient-centric clinical trials, reaching those who are sheltered at home
Drug Discovery News Placeholder Image

BRIDGE-ing the gap in Fabry disease

Protalix’s pegunigalsidase alfa posts strong results in Phase 3 BRIDGE trial
Drug Discovery News Placeholder Image

A boost to sorafenib?

MiNA presents results from study of MTL CEBPA in combo with sorafenib in liver cancer
Drug Discovery News Placeholder Image

Mixed results

MD Anderson touts candidate for lung and ovarian cancer, but breast therapeutic falls short

Contract Services

Drug Discovery News Placeholder Image

CROs create COVID partnership

U.K companies seek to provide drug discovery and development services despite pandemic restrictions
Drug Discovery News Placeholder Image

Antibody aid

CROs FairJourney Biologics and Iontas join forces to expedite identifying antibodies to fight COVID-19
Drug Discovery News Placeholder Image

The future face of clinical trials?

PPD offers digital solutions amid the COVID-19 pandemic
Drug Discovery News Placeholder Image

An API boost

Evonik announces first stage of program to increase contract manufacturing in Germany

Diagnostics

Drug Discovery News Placeholder Image

SEEK and ye shall find

Thrive’s blood test reportedly identifies multiple types of cancer
Drug Discovery News Placeholder Image

TAPS aims for gold (standard)

Base Genomics raises $11M to develop and commercialize epigenetic technology for early detection of cancer
Drug Discovery News Placeholder Image

Testing for COVID-19

Avacta and Adeptrix collaborate on new antigen test to identify coronavirus
Drug Discovery News Placeholder Image

Signature, please

Gene signature found for poor response to standard chemotherapy in rare uterine cancer

Business & Government Policy

Drug Discovery News Placeholder Image

NMPA approves Optune for glioblastoma

Adding Optune to chemotherapy more than doubled five-year overall survival rate
Drug Discovery News Placeholder Image

On the cutting edge

A roundup of instrumentation, software and other tools and technology news
Drug Discovery News Placeholder Image

Foresight and Van Heron form strategic alliance

Partnership aims to improve drug and enzyme discovery, bioremediation, cell culture work and more
Drug Discovery News Placeholder Image

Q&A: Branching out with RNA-targeting Cas systems

DDN speaks with two senior executives at Locarna to find out more about RNA-targeting Cas systems and how they work
Drug Discovery News Placeholder Image

Patent Docs: U.S. Trade Representative Releases 2020 Special 301 Report

Once again this year, the report highlights compulsory licensing as a particular concern with regard to pharmaceuticals and medical devices

Preclinical

Drug Discovery News Placeholder Image

Upregulating to success

Specially designed fusion protein ALKS 4230 could target many solid tumors
Drug Discovery News Placeholder Image

Antibacterial activity against MRSA

New class of antibiotics seems to have broad-spectrum antibacterial potential
Drug Discovery News Placeholder Image

Targeting GALC in Krabbe disease

Passage Bio presents data from animal models injected with AAVhu68

Editor's Focus

Drug Discovery News Placeholder Image

Editor’s Focus: Don’t rush a vaccine

Even with caution and care, sometimes vaccination goes awry, so we need to make sure we do it right for SARS-CoV-2 and not simply do it fast

Commentary

Drug Discovery News Placeholder Image

Out of order: All in?

Representation and diversity in life-sciences research matters as much in preclinical as it does in trials
Drug Discovery News Placeholder Image

Guest Commentary: A new wave of genomic medicine

A look at work to bring us medicines that target regulatory regions of the genome to control the expression of genes

Special Reports

Drug Discovery News Placeholder Image

Special Report on Organ Models: All in

Is model complexity helping or hindering adoption?

Feature

Drug Discovery News Placeholder Image

Focus Feature on SARS-CoV-2: Continuing the COVID fight

In this roundup of recent COVID-19 research news, we take a look at new insights into coronavirus mutation that may inform therapeutic research, discuss the idea of a global approach to a vaccine and more
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue